PARTNERSHIPS

CORPORATE | PARTNERSHIPS

Odimma Therapeutics Selected for the France 2030 Export Program
November 27, 2025May 31, 2026

Odimma Therapeutics has been selected for the France 2030 Export Program, a national initiative supporting high-potential French innovators in accelerating international development, strategic partnerships and future clinical expansion. ——————— Strengthening Odimma’s International Development Strategy Odimma Therapeutics has been selected for the France 2030 Export Program, a national initiative designed to support high-potential French innovators in…

Read More Odimma Therapeutics Selected for the France 2030 Export Program
CORPORATE | ONCOLOGY | PARTNERSHIPS | PLATFORM

€2 Million Financing Secured to Advance ODI-2001 Toward First-in-Human Clinical Trials
May 2, 2023June 10, 2026

——————— Odimma Therapeutics has secured €2 million in seed financing to support the advancement of ODI-2001, the company’s next-generation personalized immunotherapy platform candidate, toward first-in-human clinical development. The financing round was supported by Capital Grand Est, Alsace Business Angels, Angels Santé, historical shareholders, new private investors and Bpifrance, reinforcing confidence in Odimma Therapeutics’ long-term platform…

Read More €2 Million Financing Secured to Advance ODI-2001 Toward First-in-Human Clinical Trials
ONCOLOGY | PARTNERSHIPS

Odimma Therapeutics present at BIO-Europe Spring 2023
March 28, 2023June 9, 2026

——————— Odimma Therapeutics participated in BIO-Europe Spring 2023, held in Basel, Switzerland, one of Europe’s leading partnering events for the biotechnology and life sciences industry. The conference brought together biotechnology companies, pharmaceutical leaders, investors and healthcare innovators from around the world to explore strategic collaborations and emerging opportunities across the sector. Participation in BIO-Europe Spring supported…

Read More Odimma Therapeutics present at BIO-Europe Spring 2023
ONCOLOGY | PARTNERSHIPS | PLATFORM

Strategic Clinical Collaboration Established with myNEO
February 13, 2023June 9, 2026

——————— Odimma Therapeutics and myNEO announced a strategic clinical collaboration focused on advancing the development of ODI-2001, Odimma’s personalized DNA-based cancer immunotherapy platform. The collaboration combines Odimma Therapeutics’ synthetic DNA immunotherapy technology with myNEO’s artificial intelligence-driven neoantigen discovery platform to support the identification and selection of patient-specific neoantigen targets designed to generate strong anti-tumor immune…

Read More Strategic Clinical Collaboration Established with myNEO
ONCOLOGY | PARTNERSHIPS

Odimma Therapeutics Strengthens Its Platform Through Strategic Partnership with Touchlight
December 7, 2022June 9, 2026

——————— Enabling the Next Generation of Personalized Cancer Immunotherapy with Synthetic DNA Manufacturing. Odimma Therapeutics has established a strategic partnership with Touchlight, the UK biotechnology company pioneering enzymatic DNA production, to support the clinical development of its personalized cancer immunotherapy platform. The collaboration provides Odimma with access to Touchlight’s proprietary doggybone DNA (dbDNA™) technology, a next-generation synthetic…

Read More Odimma Therapeutics Strengthens Its Platform Through Strategic Partnership with Touchlight
CORPORATE | ONCOLOGY | PARTNERSHIPS

ABL and Odimma Therapeutics Partner to Advance Personalized Cancer Immunotherapy
April 17, 2022June 9, 2026

——————— Strengthening Manufacturing Capabilities for the ODI-2001 Platform. Odimma Therapeutics and ABL Europe, a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, entered into a strategic development agreement to support the advancement of ODI-2001, Odimma’s personalized cancer immunotherapy platform. Under the collaboration, ABL will manufacture the viral component of ODI-2001, a key element…

Read More ABL and Odimma Therapeutics Partner to Advance Personalized Cancer Immunotherapy